Recent Updates
Recently added Catalysts
ATHE Negative Sentiment Score: 40/100

Appendix 3Y Change of Director ' s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and docum

Wednesday, January 7, 2026 1 min read
Key Takeaway: Alterity Therapeutics Limited has filed a Change of Director's Interest Notice for director David Stamler, indicating no new acquisitions of securities but reporting the expiration of significant unlisted options. The notice reflects existing holdings, with a notable disposition of over 91 million unlisted options, which has affected the overall securities position held by the director. No new interests or securities were acquired in this notice, emphasizing a period of inactivity in terms of new investment by the director.

Market Sentiment Analysis

CONCERNS & RISKS

  • The change in interest involves options that have expired, which may raise concerns regarding the director's stock options management.
  • The absence of new acquisitions in director interests may hint at stagnation or lack of investor confidence.

Full Press Release Details

Appendix 3Y
Change of Director ' s Interest Notice
Change of Director's Interest Notice
Information or documents not available now must
be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity Alterity Therapeutics Limited
ABN 37 080 699 065
We (the entity) give ASX the following information
under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of director David Stamler
Date of last notice 21 November 2025
Part 1 - Change of director's relevant interests
In the case of a trust, this includes interests in the
trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come
within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.
Direct or indirect interest Direct and Indirect
Nature of indirect interest HSBC CUSTODY NOMINEES (AUSTRALIA)
(including registered holder) LIMITED - 133,333 - AMERICAN DEPOSITARY SHARES
(equivalent to 79,999,800 FULLY PAID ORDINARY SHARES)
Date of change (1) N/A
(2) N/A
(3) N/A
(4) N/A
(5) 06 January 2026
(6) N/A
(7) N/A
No. of securities held prior to change (1) 11,688,312 - FULLY PAID ORDINARY SHARES - DIRECT
(2) 2,380,952 - LISTED OPT EXP 31/08/2026 @ $0.01 - DIRECT
(3) 1,515,152 - LISTED OPT EXP 26/02/2027 @ $0.028 - DIRECT
(4) 40,000,200 - UNLISTED OPT EXP 21/03/2029 @ US$0.0030 - DIRECT
(5) 91,392,720 - UNLISTED OPT EXP 06/01/2026 @ $0.0320 - DIRECT
(6) 290,400,000 - UNLISTED OPT EXP 08/08/2030 @ US$0.0086 - DIRECT
(7) 133,333 - AMERICAN DEPOSITARY SHARES
(equivalent to 79,999,800 FULLY PAID ORDINARY SHARES) - INDIRECT
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Appendix 3Y
Change of Director ' s Interest Notice
Class (1) FULLY PAID ORDINARY SHARES (2) LISTED OPT EXP 31/08/2026 @ $0.01 (3) LISTED OPT EXP 26/02/2027 @ $0.028 (4) UNLISTED OPT EXP 21/03/2029 @ US$0.0030 (5) UNLISTED OPT EXP 06/01/2026 @ $0.0320 (6) UNLISTED OPT EXP 08/08/2030 @ US$0.0086 (7) AMERICAN DEPOSITARY SHARES
Number acquired (1) NIL (2) NIL (3) NIL (4) NIL (5) NIL (6) NIL (7) NIL
Number disposed (1) NIL (2) NIL (3) NIL (4) NIL (5) 91,392,720 - UNLISTED OPT EXP 06/01/2026 @ $0.0320 (6) NIL (7) NIL
Value/Consideration (1) N/A (2) N/A (3) N/A (4) N/A (5) NIL (6) N/A (7) N/A
No. of securities held after change (1) 11,688,312 - FULLY PAID ORDINARY SHARES - DIRECT (2) 2,380,952 - LISTED OPT EXP 31/08/2026 @ $0.01 - DIRECT (3) 1,515,152 - LISTED OPT EXP 26/02/2027 @ $0.028 - DIRECT (4) 40,000,200 - UNLISTED OPT EXP 21/03/2029 @ US$0.0030 - DIRECT (5) NIL - UNLISTED OPT EXP 06/01/2026 @ $0.0320 - DIRECT (6) 290,400,000 - UNLISTED OPT EXP 08/08/2030 @ US$0.0086 - DIRECT (7) 133,333 - AMERICAN DEPOSITARY SHARES (equivalent to 79,999,800 FULLY PAID ORDINARY SHARES) - INDIRECT
Nature of change (1) N/A (2) N/A (3) N/A (4) N/A (5) Options expired (6) N/A (7) N/A
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 2
Appendix 3Y
Change of Director ' s Interest Notice
Part 2 - Change of director's relevant interests
Note: In the case of a company, interests which come
within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.
Detail of contract N/A
Nature of interest N/A
Name of registered holder (if issued securities) N/A
Date of change N/A
No. and class of securities to which interest related prior to change N/A
Interest acquired N/A
Interest disposed N/A
Value/Consideration N/A
Interest after change N/A
Part 3 - +Closed period
Were the interests in the securities or contracts detailed above traded during a + closed period where prior written clearance was required? N/A
If so, was prior written clearance provided to allow the trade to proceed during this period? N/A
If prior written clearance was provided, on what date was this provided? N/A
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 3

Frequently Asked Questions

What is Appendix 3Y?

Appendix 3Y is a Change of Director’s Interest Notice submitted to ASX.

Who is the director mentioned in the notice?

The director mentioned is David Stamler of Alterity Therapeutics Limited.

What type of interests are disclosed?

Interests include fully paid ordinary shares, listed options, and American Depositary Shares.

When was the last notice submitted?

The last notice was submitted on 21 November 2025.

What change occurred on 06 January 2026?

On this date, 91,392,720 options expired, affecting the director's holdings.

Tags: ATHE Viatris Investor Conferences Healthcare Alterity Therapeutics David Stamler director interest equity options
Last updated: Jan 7, 2026